Treatment interruption in chronic HIV-1 infection: does it deliver?

被引:1
作者
Willberg, Christian B. [1 ]
Nixon, Douglas F. [1 ]
机构
[1] UCSF, Div Expt Med, San Francisco, CA 94110 USA
关键词
chronic infection; highly active antiretroviral therapy; HIV-1; treatment interruption;
D O I
10.1097/COH.0b013e3280119307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review This review sets out to overview treatment interruption in chronic HIV-1 infection: what treatment interruption promised, results from recent trials, and what the future holds. Recent findings Recent studies have produced mixed results; several trials have been prematurely halted, whereas others have reported more positive outcomes. One consistent finding has been the identification of the CD4 T-cell count nadir as a critical parameter in determining the outcome of treatment interruption. Summary The use of treatment interruption is still controversial, but it is becoming clear that certain individuals could benefit, and partial treatment interruption strategies warrant further investigation.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 50 条
  • [31] The Role of HIV-1 DNA as an Additional Marker of HIV-1 Infection
    Beloukas, Apostolos
    Paraskevis, Dimitrios
    Psichogiou, Mina
    Hatzakis, Angelos
    CURRENT HIV RESEARCH, 2009, 7 (03) : 255 - 265
  • [32] Evolution of intrahost HIV-1 genetic diversity during chronic infection
    Shriner, Daniel
    Liu, Yi
    Nickle, David C.
    Mullins, James I.
    EVOLUTION, 2006, 60 (06) : 1165 - 1176
  • [33] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Cohen, Yehuda Z.
    Caskey, Marina
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 366 - 373
  • [34] Key Concepts in the Early Immunology of HIV-1 Infection
    Siewe, Basile
    Landay, Alan
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (01) : 102 - 109
  • [35] Key Concepts in the Early Immunology of HIV-1 Infection
    Basile Siewe
    Alan Landay
    Current Infectious Disease Reports, 2012, 14 : 102 - 109
  • [36] HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy
    Steingrover, Radjin
    Pogany, Katalyn
    Garcia, Evian Fernandez
    Jurriaans, Suzanne
    Brinkman, Kees
    Schuitemaker, Hanneke
    Miedema, Frank
    Lange, Joep M. A.
    Prins, Jan M.
    AIDS, 2008, 22 (13) : 1583 - 1588
  • [37] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [38] Obstacles to successful antiretroviral treatment of HIV-1 infection:: problems & perspectives
    Potter, SJ
    Chew, CB
    Steain, M
    Dwyer, DE
    Saksena, NK
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2004, 119 (06) : 217 - 237
  • [39] Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017
    Naver, Lars
    Albert, Jan
    Carlander, Christina
    Flamholc, Leo
    Gisslen, Magnus
    Karlstrom, Olof
    Svedhem-Johansson, Veronica
    Sonnerborg, Anders
    Westling, Katarina
    Yilmaz, Aylin
    Pettersson, Karin
    INFECTIOUS DISEASES, 2018, 50 (07) : 495 - 506
  • [40] Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection
    Lewin, Sharon R.
    Murray, John M.
    Solomon, Ajantha
    Wightman, Fiona
    Cameron, Paul U.
    Purcell, Damian J.
    Zaunders, John J.
    Grey, Pat
    Bloch, Mark
    Cooper, David A.
    Kelleher, Anthony D.
    Smith, Don
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (02) : 140 - 147